2-Methylsulfinylmethylbenzofuran | 21500-29-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: 2-Methylsulfinylmethylbenzofuran
• 英文别名: 2-[(methylsulfonyl)methyl]benzofuran；2-(Methylsulfonylmethyl)-1-benzofuran
• CAS: 21500-29-8
• 化学式: C₁₀H₁₀O₃S
• 分子量: 210.254
• InChiKey: VNWGIGLKKYHGRP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  55.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  N'-(benzofuran-2-ylmethylene)methanesulfonohydrazide 在 iron(III) chloride 、 乙基溴化镁 作用下， 以 1,4-二氧六环 为溶剂， 以71%的产率得到2-Methylsulfinylmethylbenzofuran
  参考文献：
  名称：

  磺酰腙铁催化分解合成砜类化合物

  摘要：

  磺酰腙的Fe催化分解产生砜。该反应非常普遍，允许从各种芳基、烷基和 α,β-不饱和醛和酮制备砜。交叉实验表明，该反应是一个分子间过程，可以通过亚磺酸根阴离子对铁卡宾配合物的亲核攻击来进行。

  DOI：

  10.1002/ejoc.201001492

文献信息

• Alpha ketoamide compounds as cysteine protease inhibitors
  申请人：Graupe Michael

  公开号：US20070021353A1

  公开（公告）日：2007-01-25

  The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

  本发明涉及一种抑制半胱氨酸蛋白酶的化合物，特别是对卡特普西蛋白B、K、L、F和S的抑制剂，因此可以用于治疗由这些蛋白酶介导的疾病。本发明涉及包含这些化合物的制药组合物和制备它们的方法。
• Sulfonyl Containing Compounds as Cysteine Protease Inhibitors
  申请人：Mossman Craig J.

  公开号：US20080287446A1

  公开（公告）日：2008-11-20

  The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

  本发明涉及抑制半胱氨酸蛋白酶的化合物，特别是猫蛋白酶B、K、L、F和S，因此在治疗由这些蛋白酶介导的疾病方面非常有用。本发明涉及包含这些化合物的制药组合物和制备它们的方法。
• SULFONYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS
  申请人：Mossman Craig

  公开号：US20110281879A1

  公开（公告）日：2011-11-17

  The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

  本发明涉及抑制半胱氨酸蛋白酶的化合物，特别是抑制B、K、L、F和S型蛋白酶，因此在治疗由这些蛋白酶介导的疾病中有用。本发明涉及包含这些化合物的制药组合物和其制备方法。
• ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS
  申请人：Graupe Michael

  公开号：US20120190714A1

  公开（公告）日：2012-07-26

  The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

  本发明涉及一种抑制半胱氨酸蛋白酶的化合物，特别是抑制B、K、L、F和S型猫蛋白酶，因此在治疗由这些蛋白酶介导的疾病方面有用。本发明涉及包含这些化合物的制药组合物和制备它们的方法。
• US7488848B2
  申请人：——

  公开号：US7488848B2

  公开（公告）日：2009-02-10